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Abstract
DNA fluorescence in situ hybridization (FISH) technology is used to study chromosomal and
genomic changes in fixed cell suspensions and tissue block preparations. The technique is based on
specific hybridization of small labeled DNA fragments, the probes, to complementary sequences in
a target DNA molecule. Demand for FISH assays in formalin-fixed, paraffin-embedded tissues has
been increasing, mainly in conditions in which diagnosis is not achieved in cell smears or tissue
imprints, such as solid tumors. Moreover, the development of molecular targeted therapies in
oncology has expanded the applicability of tests to predict sensitivity or resistance to these agents.
The efficient use of tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR)
as therapeutical agents in advanced non-small cell lung cancer (NSCLC) depends on identification
of patients likely to show clinical benefit from these specific treatments. The EGFR gene copy
number determined by FISH has been demonstrated as an effective predictor of outcome from
NSCLC patients to EGFR TKIs; however there are pending challenges for standardization of
laboratory procedures and definition of the scoring system. This methodology article focuses on
the EGFR FISH assay. It details the scoring system used in the studies conducted at the University
of Colorado Cancer Center in which a significant association was found between increased EGFR
copy numbers and clinical outcome to TKIs, and proposes interpretative guidelines for molecular
stratification of NSCLC patients for TKI therapy.
Predictive markers in carcinomas
Improving survival of cancer patients has been a difficult
task for oncologists and all other related medical special-
ists due to the complexity of this group of diseases. Pre-
vention, early detection and improvement in therapeutic
options are the major approaches that can make a differ-
ence and have received outstanding attention from cancer
physicians, researchers and funding agencies. Much has
been learned in the last decade about tumor biology and
genetics, and a better understanding of cellular mecha-
nisms underlying the initiation and progression of cancer
has enabled the development of innovative therapeutical
strategies. Among these are the molecular-based thera-
pies, which address specific cell signaling pathways that
are important tumor-drivers.
The molecular targeted therapy field is still in its early
stages of exploration. However, exciting results have been
reported including examples of dramatic improvement in
outcome for neoplasias previously known for their poor
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prognosis. One of the first validated targeted therapies in
oncology involves metastatic breast cancer and the mono-
clonal antibody trastuzumab (Herceptin, Genentech Inc,
San Francisco CA) [1]. In approximately 20% of breast
cancers the human epidermal growth factor receptor 2
gene (c-erb-B2, ERRB2 or HER2), a member of the recep-
tor tyrosine kinase 1 (RTK1) family, is amplified and over-
expressed at the receptor level and these tumor
characteristics are significantly associated with poor clini-
cal outcome [2]. However, women with HER2 overex-
pressing metastatic breast cancer received a significant
benefit from trastuzumab, a recombinant humanized
monoclonal antibody launched as a therapeutic option in
1998. The selection of these patients for treatment has
been made by evaluating the levels of protein expression
in immunohistochemical assays (IHC) and/or the
number of copies of the HER2 gene in fluorescence in situ
hybridization assays (FISH) [3,4].
More recently, one international (HERA) and two NCI-
sponsored phase III clinical trials (NSABP B31 and
NCCTG N9831), which have enrolled more than 6,000
patients, have shown that combining paclitaxel with tras-
tuzumab after adjuvant chemotherapy significantly
improved outcome among women with surgically
removed HER-2 positive breast cancer [5,6]. These results
expanded the spectrum of breast cancer patients poten-
tially eligible for trastuzumab therapy from metastatic to
early stage breast cancer.
Non-small cell lung cancer (NSCLC) is another solid
tumor which has seen a favorable impact from targeted
therapy. Lung cancer is a significant public health prob-
lem in western countries and has long been the most com-
mon cause of cancer death [7]. NSCLC is usually
diagnosed in advanced stage, when prognosis is poor and
options for chemotherapy are limited. Another member
of the RTK1 family, the epidermal growth factor receptor
(EGFR, HER1), is long known to be overexpressed in a sig-
nificant fraction of NSCLC [8]. EGFR is a 170 kDa type I
growth factor membrane receptor with 1186 amino acids
encoded by 28 exons spanning near 190 kb on chromo-
some 7p11.2. These receptors exist as active monomers
but, upon binding to ligands such as the epidermal
growth factor (EGF) and the transforming growth factor
alpha (TGFα), they undergo conformational changes that
facilitate dimerization, either with another EGFR mole-
cule or with HER2, HER3 or HER4 molecules. The dimer-
ization is followed by intermolecular
autophosphorylation of key tyrosine residues in the acti-
vation loop of catalytic tyrosine kinase domains through
the transfer of phosphates from adenosine triphosphate
(ATP). EGFR-activated pathways include the mitogen-acti-
vated protein kinase (MAPK) pathway, which induces cell
proliferation, as well as the AKT and the signal transducer
and activator of transcription (STAT) pathways, which
contribute to cell survival.
The role of EGFR as an oncogene has been elucidated for
many years and the level of EGFR protein expression has
been shown to be elevated in multiple cancer types rela-
tive to normal tissues [9]. In lung cancer, there are several
key mechanisms for EGFR activation, such as overexpres-
sion of ligands [10], gene amplification [11,12] and acti-
vating mutations [13]. The discovery of agents with the
ability to antagonize EGFR functions in cancer cells, such
as the monoclonal antibody cetuximab (Erbitux, ImClone
Systems Inc) and the specific tyrosine kinase inhibitors
(TKIs) gefitinib (Iressa, AstraZeneca, UK) and erlotinib
(Tarceva, OSI Pharmaceuticals Inc) have heightened the
clinical interest in this growth factor receptor (14,15).
Gefitinib and erlotinib are orally active EGFR-TKIs that
block signal transduction pathways implicated in the pro-
liferation and survival of cancer cells and other host-
dependent processes promoting cancer cell growth. These
drugs have intracellular mechanisms of action and com-
pete with ATP for binding to EGFR thus directly inhibiting
EGFR autophosphorylation. In retrospective studies,
patients with advanced NSCLC treated with gefitinib or
erlotinib have shown higher rates of objective response
and longer survival than non-treated patients [16,17].
Erlotinib was shown in the NCIC-BR.21 phase III trial to
provide significant survival benefit to NSCLC patients
compared with placebo [18] and was approved for clinical
use in the US (November 2004) and Europe (June 2005).
Gefitinib failed to reach significant improvement in sur-
vival in the large randomized ISEL (Iressa Survival Evalu-
ation in Lung Cancer) study [19]. Nevertheless, there was
a clear trend towards better outcome in the treated group
of patients comparing to placebo, suggesting that there is
a subset of patients who benefit from using gefitinib.
Interestingly, in both erlotinib and gefitinib NSCLC rand-
omized trials approximately 30% of the patients died
within 4 months of treatment time, which strongly sug-
gest that there is a subset of lung cancer patients who
receive no clinical benefit from EGFR-TKI therapy.
The availability of molecular targeted therapy agents with
significant anti-tumor activity in advanced NSCLC both as
a single agent and in combination with chemotherapy
and the need to increase the efficiency of these treatments
are factors urging the development and validation of lab-
oratory tests for assessment of the EGFR status in lung can-
cer patients. Research efforts have focused on a large
number of clinical and biological factors that may predict
which NSCLC patients could benefit from molecular tar-
geted treatments and ultimately aimed to the develop-
ment of sensitive and specific laboratorial tests to screen
patients. Early on, the expression levels of EGFR was
tested without a predictive success for response to gefit-Diagnostic Pathology 2006, 1:19 http://www.diagnosticpathology.org/content/1/1/19
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inib [2022], although more recent studies in larger phase
II cohorts have detected a positive association between
high EGFR protein levels and sensitivity to both gefitinib
and erlotinib [23,24]. Activating missense mutations and
deletions in the tyrosine kinase domain of the EGFR gene
were the first molecular changes clearly associated with
objective response to gefitinib and erlotinib [25-27]. The
impact of these EGFR mutations on overall survival, how-
ever, has varied from a strong positive correlation in some
populations [28-30] to a much less marked correlation in
others [23,24]. Interestingly, EGFR mutations also con-
ferred superior outcome for chemotherapy in the TRIB-
UTE trial [31] and may even be prognostic markers
according to recent findings that non-treated patients with
mutations have longer survival [24,32].
Genomic gain for EGFR sequences detected by fluores-
cence in situ hybridization (FISH) has also been demon-
strated as an excellent predictor of response [23,24,33]
and longer survival [23,33] in large cohorts of patients
treated with gefitinib and erlotinib. More recently, molec-
ular analyses performed in patients included in the ISEL
study also have shown that longer survival was correlated
with high levels of EGFR genomic gain detected by FISH
[34]. Interestingly, if the EGFR genomic abundance in
tumors is evaluated by other techniques, such as Southern
Blotting or quantitative real-time PCR, the association
between increased gene copy numbers and sensitivity to
TKI is non-significant or marginally significant
(30,35,36). The difference probably reflects the technical
characteristics of each of the methodologies. FISH is an in
situ method that allows for identification of single cells in
the context of the tissue architecture.
Southern Blot and PCR-based techniques are global
extraction-based methods that are influenced by the dilu-
tional effects of stroma and infiltration of reactive cells.
Mutations in the tyrosine kinase domain of the HER2
gene which were similar to those described for the EGFR
gene were detected at very low frequencies in NSCLC and
are probably not clinically relevant [37,38]. Conversely,
high level of genomic gain for the HER2 gene detected by
FISH was found to be a significant predictor of outcome
to gefitinib and an enhancer of sensitivity to gefitinib in
EGFR FISH positive NSCLC patients [38].
FISH assay: principle and technical challenges
The basic technique of in situ hybridization performed on
intact cytologic material was described by Gall and Pardue
[39] employing radiolabeled probes. The development of
fluorescent labeling of nucleic acid probes [40] not only
abrogated the need for radioactive reagents but also
expanded the applicability of the technique allowing for
simultaneous analysis of numerous chromosomal regions
using distinctly labeled probes. Since then, FISH has been
increasingly accepted as a powerful research tool for inves-
tigating chromosomal changes in dividing or non-divid-
ing cells. More recently with the continuous commercial
releasing of DNA probes FISH has also become an impor-
tant technique in diagnostic pathology.
The key component of the FISH technology is the comple-
mentary property of the DNA molecule. After denatura-
tion and under proper conditions of temperature and pH,
the double stranded DNA molecule is accurately regener-
ated. If a set of single-stranded DNA fragments carrying
labeled nucleotides is provided as a probe at or soon after
denaturation, these fragments may be incorporated into
the new double stranded molecule in specific locations
determined by their nucleotide sequence. Afterwards, the
fluorescent label in the probe allows for the visualization
of the number of copies and location of the target
sequences in interphase nuclei, chromosome spreads or
DNA fibers.
In oncology, most of the biological specimens are availa-
ble as formalin-fixed, paraffin-embedded (FFPE) tumor
blocks. Two main technical strategies have been
employed for FISH analysis of these FFPE specimens: one
requires isolation of intact nuclei from thick sections of
the tumor blocks and hybridization assays are performed
in cell suspensions; the other utilizes thin cuts of the
whole paraffin-embedded blocks for assays and analyses.
In our laboratory, we favor the analysis of thin sections of
whole paraffin-embedded blocks since this strategy has
the critical advantage of maintaining intact the overall tis-
sue architecture. In consequence, it is possible to perform
direct comparison of the FISH results with the morpho-
logical details in sections stained by hematoxylin and
eosin (H&E) or immunohistochemical stains. Moreover,
in these sections it is possible to distinguish with high
confidence tumor nuclei from stromal and reactive nuclei
and to use the non-tumoral cells as internal controls for
hybridization if necessary.
A certain level of protocol customization is required for
optimum results in FISH assays performed on FFPE tissue
sections. Steps specifically important are the proper han-
dling and processing of the tissue after biopsy or resection
from the patient, the removal of tissue proteins that may
interfere with hybridization, and the tailoring of hybridi-
zation settings and post-hybridization washing condi-
tions. DNA degradation and cross-linking between the
DNA strands should be carefully prevented in the resected
or biopsied tissue, and gross dissection of large blocks in
1–3 mm thick pieces to allow a uniform, proper fixation
and incubation in 10% neutral buffered formalin for 8 to
24 hours is recommended. Degraded or cross-linked DNA
prevents probe binding whereas denatured proteins gen-Diagnostic Pathology 2006, 1:19 http://www.diagnosticpathology.org/content/1/1/19
Page 4 of 10
(page number not for citation purposes)
erate high fluorescence noise, and in both of these situa-
tions the fluorescent signals are not detected or
impossible to score. In addition, adequate fixation assures
the preservation of the tissue morphology, also a critical
parameter for FISH analysis in solid tumors.
Some pathology laboratories have been reluctant to
embrace routine FISH testing. The main alleged disadvan-
tages of using FISH in clinical diagnosis are the need for
expensive fluorescence microscopes equipped with high
quality immersion objectives and multiple fluorescence
filters. Moreover, because the fluorescent signals may fade
under bright illumination and fade upon extended stor-
age, the hybridization results must be permanently
recorded with digital cameras. Considering laboratory
personnel, there is also a negative impact from the fact
that the protocol is laborious, microscope analysis
requires specialized training and there is an insufficient
labor force to absorb incremental testing. However, these
factors are surely improving over time. Cost of fluores-
cence microscopes and imaging systems are decreasing
and automation of many laboratorial and analytical steps
is available from more than one commercial source. Addi-
tionally, clinical laboratories both in private and in aca-
demic settings have lately seen an increase in the number
of requests for FISH testing in genetic diseases, hemato-
logical neoplasias, and solid tumors. The expansion of
trastuzumab therapy from metastatic to early breast can-
cer following recent findings that trastuzumab was effec-
tive in adjuvant settings [5,6] has already escalated the
demand for HER2 FISH assays. Validation of the EGFR
FISH test to select NSCLC patients for therapy with EGFR-
TKIs will also bring a large number of specimens to the
clinical pathology laboratories. Moreover, EGFR-TKIs are
considered as treatment options in other tumors such as
colorectal, head and neck and pancreatic carcinomas
[14,15] and the FISH assay could prove useful for selec-
tion of these patients too. Therefore, the increasing appli-
cability associated with factors such as the decreasing
equipment costs and release of automated platforms for
assaying and analyses is expected to significantly expand
the community-based experience in FISH technology in
the near future.
Guidelines for the EGFR FISH assay and 
microscope analysis
The standard protocol for assaying and analyzing the copy
number of the EGFR gene in FFPE lung sections in our lab-
oratory using the SpectrumOrange LSI EGFR/Spectrum-
Green CEP 7 probe set (Vysis/Abbott Molecular, IL) is
briefly described. Typically we receive one H&E-stained
and two sequential blank sections cut at 4 um and
mounted on positively charged slides. Regions rich in
tumor cells are identified in the H&E stained slide and the
smallest area of interest necessary to cover a significant
fraction of tumor is defined for hybridization and marked
in the back of the blank slide with diamond-tipped scribe.
The protocol is customized depending on the size of the
section. The blank slide from a biopsy is incubated over-
night at 56°C, while larger sections are incubated for 2 to
4 hours. Sections are initially passed through three 10-
min CitriSolv (Fisher Scientific) incubations for deparaffi-
nization, followed by 10-min immersion in 100% etha-
nol. Subsequently, biopsy specimens are treated with
sequential incubations in 2 × SSC at 75°C for 6 min, in
0.25 mg/ml Proteinase K/2 × SSC at 37C for 10 min, and
in 2 × SSC for 5 min at room temperature. Incubation
times in 2 × SSC and Proteinase K are longer for larger
resected specimens, going up to 20 min. Slides are then
immersed in graded alcohol series (75°C, 85°C, 100°C),
air-dried, and the probe is applied onto the area of inter-
est. Based on the size and shape of this area, a specific
glass coverslip is selected for each section (12 mm or 15
mm diameter, 10 × 22 mm, 18 × 18 mm, 22 × 22 mm)
and the amount of probe to be used is calculated based on
the area of the coverslip to maintain the final probe con-
centration specified by the manufacturer. The hybridiza-
tion area is covered with the selected coverslip and sealed
with rubber cement. Specimens are heated in a dry oven
for 10–15 min at 80°C for denaturation of the target and
probe DNAs and are subsequently incubated overnight at
37°C in humidified chamber. Upon completion of the
hybridization time, the rubber cement seal is stripped off,
the coverslip is gently removed, and the slides are imme-
diately incubated in 2 × SCC/0.3% NP-40 at 73°C for 2
min. Alternatively, 1.5 M urea/0.1 × SSC at 45°C for 30
minutes can also be used. After a rapid wash in 2 × SSC at
room temperature and dehydration in graded ethanol
series, DAPI in anti-fade solution (0.3 ug DAPI in Vectash-
ield mounting medium, Vector Laboratories) is pipetted
onto the specimen and the area is covered with a 20 × 40
mm coverslip. Following this relatively simple protocol,
we have found that the FISH assay is successful in a great
majority of FFPE specimens (>90% in specimens from
large multicenter retrospective studies, ~100% in recently
fixed clinical specimens).
We use epifluorescence microscopes equipped with 100
W mercury-arc lamp and fitted with low power (10×) and
high power (40× and 100×) high-quality objectives, in
combination with single (red, green, blue), dual (red/
green) and triple-band pass (red/green/blue) interference
filters (Chroma Technology) for simultaneous detection
of both EGFR and CEP7 targets in the nuclear context.
Digital documentation is secured for two microscope
fields (or more in heterogeneous specimens) and a Z-
stacking feature is used to account for the multiple focal
planes when imaging. Each specimen is evaluated by two
independent readers, each of whom analyzes at least 50
cells selected from at least 4 tumor areas. If concordantDiagnostic Pathology 2006, 1:19 http://www.diagnosticpathology.org/content/1/1/19
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results are achieved, the result is assigned to the specimen.
If there is disagreement, a 3rd reader performs the analysis
and the result reached by the majority of the readers is
assigned to the specimen.
Lung tumors may be highly heterogeneous with inter-
spaced clusters of tumor cells displaying more or less
severe molecular abnormalities, a characteristic that
emphasizes the need to comprehensively scan several
tumor areas in each section. It is also critical to perform
microscope analysis of FISH signals in sections of solid
tumors in parallel with the investigation of corresponding
H&E stained sections in order to achieve a level of histo-
logical interpretation of the section that cannot be pro-
vided by the DAPI staining. For practical purposes, the
main steps in microscope analysis and interpretation are
summarized in Table 1.
EGFR FISH patterns and NSCLC patient 
stratification
The EGFR FISH results obtained in the scored tumor cells
are summarized by four indexes representing the (a) per-
centage of cells carrying at least 4 copies of the EGFR sig-
nals, (b) percentage of cells carrying at least 15 copies of
the EGFR signals, (c) average ratio of EGFR gene signals/
CEP 7 signals per cell, and (d) presence of loose or tight
gene clusters or atypically large gene signals. Guidelines
for classification of specimens as EGFR FISH positive or
negative based on these indexes are listed in Table 2. In
short, tumors with at least 40% of cells displaying at least
4 copies of the EGFR signals or with EGFR gene amplifica-
tion are classified as EGFR FISH positive. Specimens with
less than 40% of cells displaying at least 4 copies of the
EGFR signals and no gene amplification are classified as
EGFR FISH negative.
The cut-off values for stratification of patients in the EGFR
FISH positive or EGFR FISH negative categories were
determined in a retrospective study performed in
advanced NSCLC patients treated with gefitinib [23].
These patients were initially stratified into six FISH groups
according to an increasing number of copies of the EGFR
gene in their tumor cells (disomy, low trisomy, high tri-
somy, low polysomy, high polysomy, and gene amplifica-
tion) and these groups were evaluated for clinical
outcome. The relationship between FISH results and the
clinical outcome represented by response to gefitinib,
time to disease progression after treatment, and survival
after treatment favored the combination of the four FISH
groups with no or low genomic gain for EGFR (disomy to
low polysomy) as FISH negative and the combination of
the two groups with high genomic gain for EGFR (high
polysomy and gene amplification) as FISH positive. In
that study, among the patients with tumors in the EGFR
FISH disomy category there were no responders, 75% of
the patients progressed, median time to progression was
2.5 months, and overall survival was 7 months. Similarly
poor outcome was noted among the patients with tumors
categorized with EGFR FISH trisomy and low polysomy
patterns. In contrast, patients with tumors showing EGFR
FISH positive pattern included 86% of the responders and
only 33% of the patients with progressive disease. Median
disease free survival was 6.3 months and overall survival
was 9 months in this subset of patients. Although in that
retrospective study the response rate was higher and
median survival was longer in gefitinib treated patients
Table 1: Guidelines for Microscope Analysis of NSCLC tissue sections hybridized with the SpectrumOrange LSI EGFR/SpectrumGreen 
CEP 7 FISH probe set (Vysis/Abbott Molecular) at UCCC.
• Examine the parallel H&E stained section to locate areas rich in tumor cells. Recognize the tumor pattern, verify the cell density in the tumor 
areas and the size of the tumor nuclei.
• Identify 4–5 distinct tumor areas and define tissue landmarks for them. Perform this selection with the assistance of a lung pathologist.
• Use low power objective (20× or 40×) and DAPI filter to re-find the selected tumor areas in the FISH section based on the landmarks recognized 
in the H&E slide. Record the location of these areas.
• Move to a high power objective (100×), change to red, green, double red/green and/or triple blue/red/green band pass filters to inspect quality of 
the hybridization.
• The normal green signals (CEP 7) signals should be bright, compact (occasionally slightly stringy or diffuse) oval shapes. The red (EGFR) signals 
should be bright, small round shapes, commonly adjacent to a green CEP 7 signal. The green CEP7 green signal should be larger and brighter 
than the EGFR red signal.
• Background should appear dark and free of fluorescence particles or haziness.
• At least 75% of cells in the selected tumor areas should display hybridization signals not hampered by background noise for the specimen to 
qualify for analysis.
• Select approximately 10–20 representative nuclei for analysis in 2–3 microscope fields in each selected tumor area. Record the number of red and 
green signals for each individual nucleus in the FISH analysis worksheet. Select nuclei should have:
• Not less than median diameter compared with overall tumor nuclei to reduce the effect of the nuclear truncation.
• Unambiguous borders and objectively interpretable signals.
• At least one signal for each target.
• Scan the focus through the entire depth of the section to ensure that all signals are identified within each nucleus.
• Score a minimum of 50 representative nuclei per specimen (or 30 cells when gene amplification is present).
• Document results capturing images of representative fields (two if the specimen is homogeneous or more if the specimen is heterogeneous).Diagnostic Pathology 2006, 1:19 http://www.diagnosticpathology.org/content/1/1/19
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harboring EGFR gene amplification than high polysomy,
differences were not significant and the clinical outcomes
in both of these subsets differed significantly from the
FISH negative patients.
Similar positive association of EGFR gene copy number
with outcome to EGFR-TKIs was found by our UCCC lab-
oratory in three distinct cohorts treated with the EGFR TKI
gefitinib [23,32,34] and in an advanced NSCLC cohort
treated with erlotinib in which the molecular markers
were evaluated at the Princess Margaret Hospital in
Toronto, Canada (22). In each of these studies, which
included unselected cohorts of patients, the EGFR FISH
assay identified a subset of 30–40% of NSCLC patients
who were likely to benefit from TKIs. Prospective studies
are ongoing for validation of the EGFR FISH assay as a pre-
dictive biomarker for EGFR inhibitors. In a preliminary
report of the ONCOBELL trial currently being conducted
in Italy [41], response rate to gefitinib was 68% in the
EGFR-FISH positive and 9% in the EGFR FISH negative
NSCLC patients (p < 0.001). Confirmation of the optimal
cut-off values in the frequency of tumor cells displaying
high gene copy number for identification of EGFR FISH
positive patients based on the best fit analysis of clinical
outcome to the molecular target therapies is also under
way.
Chromogenic in situ hybridization (CISH) is another tis-
sue-based technique with the advantage of using bright-
field microscopy [42]. However, CISH has lower level of
resolution than FISH and is set for single-color assay
therefore preventing the simultaneous use of a control
probe for aneusomy. Although we acknowledge the
potential applicability of CISH in ascertaining HER2 gene
amplification in breast cancer patients who are candidates
for trastuzumab therapy, the scoring system proposed for
EGFR FISH in NSCLC currently cannot be extrapolated to
CISH technology.
EGFR gene amplification in non-small cell lung 
carcinoma
In breast cancer, amplification of the HER2 gene usually
occurs as a large cluster of gene signals surrounding a CEP
17 signal and is classically defined by a ratio of gene to
chromosome 17 signals ≥ 2 [3,4]. The classification of
EGFR gene amplification in NSCLC is more challenging.
One determinant of the complexity is the high frequency
of supernumerary copies of CEP 7 (Figure 1A, B) that
dilutes the gene gain when only the ratio gene/chromo-
some is used as an index. Another determinant is the vari-
ety of mechanisms of amplification of the EGFR gene. In
analyses of large numbers of primary or metastatic NSCLC
specimens, we recognized six patterns of EGFR gene
amplification, as detailed in Table 3 and illustrated in Fig-
ures 1 and 2. The prevalent pattern (~60%) is the classical,
large and relatively loose clusters of more than 20 copies
of gene signals that is seen when the amplicon is pre-
sented as a homogeneously staining region (hsr). In these
cases, the ratio EGFR/CEP 7 is likely ≥ 2, despite the usual
gain of CEP 7 signals (Figure 2A). A fraction of approxi-
mately 10%–15% of amplified tumors displays a second
pattern represented by clusters including 4 to 10 copies of
EGFR. Combination of these small clusters with extra cop-
ies of CEP 7 in each tumor cell usually lowers the ratio
EGFR/CEP 7 to less than 2. In the third pattern, found in
15–20% of EGFR amplified cases, the EGFR amplicon
includes CEP 7 sequences, which results in co-localized
clusters of EGFR and CEP 7 signals (Figure 2B). A fourth
pattern is represented by a smaller set of approximately
5% of the amplified cases that display atypically large and
bright gene signals most likely representing amplification
of a DNA segment encompassed by the EGFR probe (Fig-
ure 2C). In the fifth and rarer pattern (~1%) the amplified
EGFR sequences are borne on unstable, extrachromo-
somal double minutes (Figure 1C). The sixth pattern
included as gene amplification is a notably high EGFR
copy number (≥15 EGFR signals in ≥10% of cells) as con-
sequence of chromosomal aneusomy (Figure 2D), which
accounts for approximately 5% of the amplified tumors.
Except for the fourth and fifth FISH patterns described
above, all others have been similarly observed in met-
Table 2: UCCC criteria for stratification of NSCLC patients according to the EGFR FISH assay.
EGFR FISH Positive
• Specimens with EGFR gene amplification, defined as:
(a) EGFR gene to CEP 7 ratio ≥ 2
(b) Small gene cluster (4–10 copies) or innumerable tight gene cluster in >10% the tumor cells independent of the EGFR to CEP 7 ratio
(c) Larger and brighter EGFR signals than CEP 7 signals in >10% the tumor cells while EGFR signals are smaller than the CEP 7 signals in the 
adjacent stromal and reactive cells independent of the EGFR to CEP 7 ratio
(d) >15 copies of the EGFR signals in >10% of tumor cells independent of the EGFR to CEP 7 ratio
• Specimens with ≥ 40% of cells displaying ≥ 4 copies of the EGFR signal
EGFR FISH Negative
• Specimens without gene amplification as defined above and with <40% of cells displaying ≥ 4 copies of the EGFR signalDiagnostic Pathology 2006, 1:19 http://www.diagnosticpathology.org/content/1/1/19
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aphase and interphase cells of NSCLC cell lines investi-
gated in our laboratory [43].
The intratumoral heterogeneity common in NSCLC adds
to the described complexity. EGFR gene amplification
may be homogenously distributed over the tumor areas in
a tissue section or may be confined to certain cells. In this
case, it may be present in specific foci of tumor cells or dif-
fusely interspaced among non-amplified tumor nuclei.
These findings have supported the definition of EGFR
amplification in lung tumors in our studies based on a
minimum percentage of cells (≥10%) instead of using the
gene to chromosome ratio >2 classically accepted and
approved by the US Food and Drug Administration (FDA)
for the HER2 gene in breast cancer. In the heterogeneous
specimens, the ratio EGFR to CEP 7 can be significantly
impacted by the selection of cells to be scored, thus sus-
taining the proposed scoring in multiple tumor areas as
an attempt to obtain a more representative result.
Conclusion
The EGFR FISH assay according to the described scoring
criteria developed in our laboratory at the University of
Colorado Cancer Center allows for the assessment of
EGFR gene patterns that can assist in the stratification of
advanced NSCLC patients for treatment with the EGFR-
TKIs gefitinib and erlotinib. The assay is readily applicable
to thin sections of standard FFPE tumor blocks and results
can be determined in nuclei selected within the correct
histological context. However, we acknowledge that addi-
tional information from prospective clinical trials is still
required before recommendations relating to patient
management can be made. Studies combining EGFR FISH
with other molecular markers such as EGFR IHC and
mutation analyses are also ongoing, and it is possible that
a panel of tests ultimately prove to be better than any sin-
gle test for NSCLC patient selection for TKI.
The utility of the FISH assay in FFPE sections is expected
to broaden in the future as additional chromosomal and
genomic abnormalities are identified as prognostic and
predictive molecular markers in human cancers. Numer-
ous solid tumors have been considered for molecular tar-
geted therapies and selection of patients for those
treatments will very likely be dependent on the tumor
molecular profile. It is critical to define guidelines for lab-
oratorial assays and interpretation of the results for each
specific case and to put in place successful quality control
and quality assurance programs to qualify clinical labora-
tories to offer these tests.
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Table 3: UCCC scoring and interpretation of different types of EGFR gene amplification in NSCLC specimens.
Pattern Description Scoring Criteria Number of 
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Large, loose clusters of red (EGFR) signals Count signals thoroughly 
and calculate the FISH 
indexes
30 >2 GA
Small, loose clusters of red (EGFR) signals Count signals thoroughly 
and calculate the FISH 
indexes
30 >2 or ~1 if high level 
of aneusomy 7 is 
present
GA if ratio >2 GA if 
clusters are present in 
>10% cells, independent of 
ratio
Large, loose co-localized clusters of red 
(EGFR) and green (CEP 7) signals
Count signals thoroughly, 
account for the 
innumerable signals using 
the symbol greater than (>) 
in front of the final 
counting
30 ~1 GA if clusters are present 
in >10% cells
Tightly packed, innumerable cluster of red 
(EGFR) signals or atypically large red (EGFR) 
signal, consistently bigger than the green 
(CEP 7) signal in the tumor cells but smaller 
in the adjacent stromal and reactive cells
Count signals in at least 50 
cells and identify each cell 
displaying this specific 
feature in the analysis sheet
≥ 50 ~1 GA if tight clusters or 
atypical red signal is 
present in >10% cells
EGFR as double minutes Count signals thoroughly 
and calculate the FISH 
indexes
30 >2 GA
Very high number of balanced red (EGFR) 
and green (CEP 7) signals
Count signals in at least 50 
cells
≥50 ~1 GA if >10% cells have ≥ 15 
red (EGFR) signals
* GA = EGFR gene amplificationDiagnostic Pathology 2006, 1:19 http://www.diagnosticpathology.org/content/1/1/19
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